Login:
 
Hypoglycaemia risk with combination therapy in type 2 diabetes.Practitioner 2016; 260 (1794):9

Hypoglycaemia risk with combination therapy in type 2 diabetes

23 Jun 2016Registered users

A meta-analysis has suggested that the addition of a DPP-4 inhibitor to existing sulphonylurea (SU) therapy is associated with a 50% increased risk of hypoglycaemia in type 2 diabetes patients and one excess case for every 17 patients treated in the first six months. These findings emphasise the importance of following the recommendation to reduce SU dose when commencing a DPP-4 inhibitor.

Registered usersThis article can only be accessed if you are a registered user of thepractitioner.co.uk or a subscriber to The Practitioner.

To buy this article (£25+tax) copy the article citation above and click Buy article